Radia Theranostics Inc. is a Canadian company holding exclusive global distribution rights — outside the United States — for a portfolio of clinical-grade isotopes for targeted alpha therapy and precision oncology diagnostics. We connect world-class production with cancer care worldwide.
About Radia Theranostics
Radia Theranostics Inc. is a British Columbia–incorporated Canadian company. We hold exclusive global distribution rights, outside the United States, for a portfolio of clinical-grade medical isotopes produced by contracted GMP-certified manufacturing partners. Our mandate is singular: expand reliable patient access to life-saving radiopharmaceuticals in markets where supply has historically been constrained or absent.
Master distribution agreement covering all territories outside the United States. Structured to support exclusive territorial sub-licences for qualified regional partners.
Domiciled in British Columbia — leveraging Canadian government trade programs, EDC export financing, and Trade Commissioner Service support in every priority market.
We manage international import licences, nuclear substance approvals, and radiopharmaceutical regulatory filings in each territory — handling the complexity so partners focus on patients.
Active in Year 1 markets with partners in place. Pipeline markets in final qualification — with further expansion planned as our isotope portfolio grows.
Isotope Portfolio
All isotopes are sourced from GMP-grade cyclotron production facilities and distributed under strict regulatory compliance. Our portfolio is anchored in therapeutic alpha emitters for targeted alpha therapy, with precision diagnostic tracers to follow.
Actinium-225 is the cornerstone of next-generation targeted alpha therapy (TAT). When conjugated to tumour-targeting vectors, Ac-225 delivers a localised cascade of alpha particles directly to cancer cells — causing highly lethal DNA damage with minimal collateral toxicity to surrounding healthy tissue.
Clinical demand for Ac-225 is rapidly outpacing global supply, driven by the emergence of PSMA-targeted therapies in prostate cancer and an expanding pipeline of indications. Radia Theranostics is positioned to close this supply gap across markets where access has historically been limited or absent.
Expanding Portfolio — Coming Soon
Cyclotron-produced alpha emitter with a 7.2-hour half-life. Highly precise, high-LET radiotherapy with minimal systemic exposure. Requires just-in-time delivery co-ordinated to the hour from production to patient.
Distribution rights — advanced discussions
A true theranostic isotope — used for both PET/CT imaging and targeted radiotherapy research. The 12.7-hour half-life supports multi-centre distribution without dedicated on-site production infrastructure.
Portfolio addition planned — Year 1
The workhorse of modern oncology PET imaging. Used in PSMA and DOTATATE scans for prostate cancer and neuroendocrine tumour staging. High demand across all priority markets in Asia-Pacific and Europe.
Portfolio addition planned — Year 1
The foundation of FDG-PET imaging globally. At 110 minutes half-life, F-18 distribution requires regional production partnerships and established cold-chain networks at each hub.
Portfolio addition planned — Year 1–2
An emerging immuno-PET isotope with a 78.4-hour half-life, enabling antibody-based imaging and pharmacokinetic studies for ADC development programs in pharmaceutical research.
Portfolio addition planned — Year 2
Radia's portfolio is designed to grow alongside the clinical radiopharmaceutical pipeline. Contact us to discuss isotope requirements and territory availability for unlisted radioisotopes.
Enquire about specific requirements
The Radia Model
Radia operates as a master distributor — holding global rights from the production source and deploying qualified regional partners who hold local regulatory licences, cold-chain infrastructure, and hospital relationships in each territory.
Medical isotopes produced to GMP standard at contracted cyclotron facilities. Quality documentation and certificate of analysis accompany every shipment.
Radia holds exclusive global rights (excluding USA) and manages regulatory approvals, international quality systems, import documentation, and logistics co-ordination.
Vetted sub-distribution partners in each territory hold local licences and manage final-mile delivery to nuclear medicine centres, hospitals, and radiopharmacies.
Isotopes arrive at nuclear medicine centres and radiopharmacies in compliant condition, ready for administration under physician supervision.
Half-life logistics are engineered into every plan. For short-lived isotopes including Astatine-211 (7.2 h) and Fluorine-18 (110 min), Radia's distribution model treats production scheduling, air freight routing, customs clearance, and final-mile delivery as a single co-ordinated chain. Every market entry plan is validated against isotope decay constraints before commercial launch.
Priority Markets
Seven priority markets identified by nuclear medicine infrastructure, regulatory pathway clarity, isotope demand, and availability of qualified regional partners.
Partner confirmed. BAPETEN nuclear substance licensing pathway mapped. Growing infrastructure centred on RS Kanker Dharmais and major teaching hospitals.
Year 1 — ActivePartner confirmed. PNRI and Department of Health regulatory engagement underway. Key centres: Philippine General Hospital, St. Luke's Medical Center.
Year 1 — ActiveEurope's largest nuclear medicine market. BfArM/BfS pathway under assessment. Partner discussions active with established regional distributors.
Year 1–2 PipelinePMDA/NRA framework applicable. High TAT clinical trial activity and significant unmet demand for Ac-225 in advanced prostate cancer programmes.
Year 1–2 PipelineARPANSA/TGA pathway applicable. Strong academic medical centre infrastructure. PBS reimbursement environment assessed for TAT therapies.
Year 1–2 PipelineMFDS/NSSC framework. Advanced nuclear medicine sector with existing cyclotron capability; opportunity for supply augmentation partnerships.
Year 1–2 PipelineMHRA/ONR pathway. NHS nuclear medicine programmes and academic trial centres represent significant demand. Post-Brexit import licensing requirements assessed.
Year 1–2 PipelineBecome a Partner
Radia Theranostics is actively seeking qualified sub-distribution partners in all priority markets. Regional partners receive exclusive territorial rights for specific isotopes, full regulatory and commercial support from our Canadian headquarters, and supply security under the master distribution agreement.
Active nuclear material import licence or demonstrated pathway to obtain one. Experience with radiopharmaceutical regulatory bodies (BAPETEN, PNRI, PMDA, MFDS, TGA, MHRA, BfArM or equivalent).
Shielded transport capability, certified radioactive material handling, and same-day last-mile delivery network to nuclear medicine centres in territory.
Established relationships with nuclear medicine departments, oncology centres, and radiopharmacies in the target territory, with capacity to develop new accounts.
Demonstrated capacity to manage procurement, regulatory investment, and working capital requirements of a medical radioisotope distribution operation.
Complete the form below. Our business development team will respond within 48 hours. All applications are treated in strict confidence.
Thank you for your interest in partnering with Radia Theranostics. Our business development team will review your application and respond within 48 hours.
All applications are treated in strict confidence in accordance with our Privacy Policy. We do not share applicant information with third parties.
Frequently Asked Questions
Radia Theranostics Inc. is a British Columbia–incorporated Canadian company holding exclusive global distribution rights, outside the United States, for a portfolio of clinical-grade medical isotopes produced by GMP-certified manufacturing partners.
Our current portfolio is anchored by Actinium-225 (Ac-225) for targeted alpha therapy. Distribution agreements for additional isotopes — including At-211, Cu-64, Ga-68, F-18, and Zr-89 — are in development. Contact us for current availability and territory-specific timelines.
No. Radia Theranostics is a dedicated distributor. All isotopes are produced by contracted GMP-certified cyclotron manufacturing facilities. This model allows us to focus entirely on regulatory strategy, logistics, and commercial partnerships across global markets.
Radia holds distribution rights for all territories outside the United States. Year 1 active markets are Indonesia and the Philippines. Year 1–2 pipeline markets include Germany, Japan, Australia, South Korea, and the United Kingdom. We welcome enquiries from all other territories.
Our logistics model is engineered around the physical constraints of each isotope. For Ac-225 (9.9-day half-life), multi-day international air freight is viable. For shorter-lived isotopes such as At-211 (7.2 hours), production-to-delivery is co-ordinated to the hour with regional partners before commercial launch in a territory.
Requirements vary by jurisdiction. Radia manages international import licence applications and nuclear substance regulatory filings in each territory as part of the distribution partnership. We have mapped regulatory pathways for all seven priority markets. Contact us for a territory-specific regulatory overview.
Regional partners enter into a formal sub-distribution agreement with Radia, granting exclusive or non-exclusive territorial rights for specific isotopes. Partners hold all in-territory regulatory licences, operate local cold-chain infrastructure, and manage hospital and pharmacy relationships. Radia provides supply, quality documentation, and commercial support.
Complete the Partner Application form on this page. Our business development team will review your submission and respond within 48 hours. We welcome enquiries from radiopharmaceutical distributors, nuclear pharmacies, hospital networks, and life sciences companies with relevant infrastructure and regulatory experience.